Indivior (INDV) AI Stock Analysis

• Market Cap: £2.14B
• Dividend Yield: N/A
• Average Volume (3M): 2.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.73
• Revenue Growth: 4.09%
• EPS Growth: -640.24%
• Country: US
• Employees: 1,030
• Sector: Healthcare
• Sector Strength: 38
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.51
• Shares Outstanding: 124,769,530
• 10 Day Avg. Volume: 2,550,268
• 30 Day Avg. Volume: 2,291,123
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £18.34
• Price Target Upside: -16.65% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 70 Outperform
• Price Target: $19.00 ▼(-13.64% Downside)

Indivior's strong technical performance and improving financial trajectory are tempered by valuation concerns and recent revenue challenges. The company's strategic initiatives and market position offer potential for recovery, but investors should be cautious of overbought signals and balance sheet weaknesses.

Positive Factors

Financial Performance

1Q25 group results beat expectations, with group revenues declining a more modest 6% compared to consensus expectations of a 14% decline.

Market Position

Sublocade retains a dominant market share with approximately 80% share within the cohort for buprenorphine-based LAI and 60% share of LAI-naive patients.

Operational Efficiency

The company achieved significant opex savings, contributing to the group sales beat expectations by 9%, gross margin by 10%, and adj. EBIT by over 40%.

Negative Factors

Competition

Sublocade was ultimately $100M below initial 2024 guidance from competitor Brixadi share gains and also CJS funding disruption.

Market Challenges

CJS funding gaps remain a key headwind, affecting Sublocade sales and contributing to a 38% decline in the CJS market.

Operational Costs

Analyst thinks INDV is overspending on G&A and the operational structure can be much more efficient.

Indivior Business Overview & Revenue Model

Company Description

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

How the Company Makes Money

Indivior makes money primarily through the sale of its pharmaceutical products, particularly those targeting opioid addiction treatment. The company's revenue model is based on the commercialization of its proprietary medications, including Suboxone Film and Sublocade, which are sold to healthcare providers, pharmacies, and government agencies. Indivior's earnings are significantly influenced by its market share in the addiction treatment sector, ongoing clinical trials, and regulatory approvals that allow for the expansion of its product offerings. Additionally, partnerships with healthcare organizations and distribution agreements play a crucial role in broadening the reach of its products and enhancing revenue streams.

Indivior Financial Statement Overview

Summary

Indivior's financials show a positive trajectory with strong revenue growth and improved profitability. The income statement reflects recovery, and cash flow indicates strong cash generation. However, the negative equity position and low EBIT margin are concerns.

Income Statement

Indivior's income statement shows a strong recovery and growth trend, with a significant increase in total revenue from $647M in 2020 to $1.17B in TTM. The company achieved a positive net income in TTM after a period of losses, indicating improved profitability. Gross profit margins have remained strong, and the net profit margin turned positive in TTM, reflecting effective cost management. However, the EBIT margin is relatively low, suggesting potential areas for operational efficiency improvements.

Balance Sheet

The balance sheet reveals a negative stockholders' equity position in TTM, which is a significant weakness, as it suggests more liabilities than assets. Despite this, the company has managed its debt levels well, with a low total debt. The equity ratio is negative, reflecting the need for strengthening equity capital. However, the low debt-to-equity ratio indicates that the company is not heavily leveraged, which is a positive aspect.

Cash Flow

Cash flow analysis shows a significant improvement in operating cash flow, turning positive in TTM. Free cash flow has also grown substantially, reflecting strong cash generation capabilities. The operating cash flow to net income ratio is robust, indicating efficient cash management. However, the fluctuation in free cash flow over the years points to potential volatility in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.17B	1.19B	1.09B	884.63M	777.48M	689.68M
Gross Profit	986.00M	957.00M	907.00M	715.75M	639.87M	573.49M
EBITDA	263.00M	84.00M	68.61M	-44.18M	233.93M	-128.98M
Net Income	128.00M	2.00M	2.00M	-52.04M	205.00M	-157.76M
Balance Sheet
Total Assets	1.45B	1.32B	1.95B	1.78B	1.83B	1.53B
Cash, Cash Equivalents and Short-Term Investments	510.00M	320.00M	410.00M	897.83M	1.10B	858.00M
Total Debt	58.00M	375.00M	282.00M	278.50M	285.44M	285.00M
Total Liabilities	1.71B	1.67B	1.95B	1.73B	1.63B	1.45B
Stockholders Equity	-257.00M	-348.00M	67.90M	51.28M	202.60M	82.00M
Cash Flow
Free Cash Flow	189.00M	7.00M	-368.00M	-9.82M	313.55M	-210.00M
Operating Cash Flow	236.00M	36.00M	-315.00M	-3.93M	346.97M	-205.73M
Investing Cash Flow	20.00M	69.00M	-100.36M	-218.95M	-13.76M	-4.26M
Financing Cash Flow	-50.00M	-102.00M	-46.00M	-98.18M	-92.39M	-10.66M

Indivior Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INDV, the sentiment is Positive. The current price of 22 is above the 20-day moving average (MA) of 18.18, above the 50-day MA of 15.72, and above the 200-day MA of 11.85, indicating a bullish trend. The MACD of 1.92 indicates Negative momentum. The RSI at 88.73 is Negative, neither overbought nor oversold. The STOCH value of 95.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INDV.

Indivior Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	74 Outperform	$1.11B	8.91	18.32%	―	1.37%	-18.10%
ANIP	73 Outperform	$1.77B	―	-2.82%	―	38.68%	-160.14%
INDV	70 Outperform	£2.14B	―		―	4.09%	-640.24%
SUPN	65 Neutral	$2.31B	36.03	6.38%	―	5.55%	1145.24%
PCRX	59 Neutral	$1.13B	―	-15.57%	―	2.25%	-301.59%
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
EVO	47 Neutral	$1.40B	―	-20.41%	―	0.45%	-125.61%

Indivior Corporate Events

Indivior Appoints Tony Kingsley as Non-Executive Director

On June 24, 2025, Indivior PLC announced the appointment of Tony Kingsley as a non-executive director, effective July 1, 2025. Kingsley, an accomplished biopharmaceutical executive, is expected to bring significant commercial and clinical development experience to Indivior, enhancing its efforts to advance its mission and strengthen its position in delivering treatments for opioid use disorder. His appointment aligns with Indivior’s relationship agreement with affiliates of Oaktree Capital Management, and he will be compensated in line with other non-executive directors.

The most recent analyst rating on (INDV) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.